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1 Drug description 
Generic/Brand name/ATC code:  
Bevacizumab / Avastin® / L01XC07 
Developer/Company:  
Roche Registration Ltd. 
Description:  
Bevacizumab (Avastin®) is a recombinant monoclonal antibody targeting the 
vascular endothelial growth factor receptor (VEGFR). By inhibiting the 
binding of VEGF which is responsible for the growth of blood vessels, it pre-
vents the development of the blood supply of cancer cells and thus inhibits 
tumour angiogenesis [1]. 
Bevacizumab (Avastin®) is administered as an infusion (drip into a vein). 
The dosage ranges from 5 mg/kg of body weight to 15 mg/kg of body weight 
depending on the type of cancer [1]. The recommended dose of bevacizumab 
(Avastin®) in combination with paclitaxel or pegylated liposomal doxorubi-
cin for the treatment of recurrent epithelial ovarian, fallopian tube and pri-
mary peritoneal cancer is 10 mg/kg of body weight given once every two 
weeks. In combination with topotecan, the recommended dose of Avastin® is 
15 mg/kg of body weight once every three weeks. It should be administered 
as an intravenous infusion [1]. 
Bevacizumab (Avastin®), in addition to carboplatin and paclitaxel as a front-
line treatment for epithelial ovarian, fallopian tube and primary peritoneal 
cancer, is given for up to six cycles of treatment followed by continued use of 
bevacizumab (Avastin®) as single agent. Treatment can be continued either 
until disease progression, for a maximum of 15 months or until unaccepta-
ble toxicity, whichever occurs earlier [1]. 
Side effects commonly observed are hypertension, fatigue, diarrhoea, 
abdominal pain, as well as asthenia. Gastrointestinal perforation, 
haemorrhage and arterial thromboembolism are the most severe side effects 
of Avastin® [1, 2]. People who are allergic to bevacizumab, recombinant 
antibodies or any other ingredients must not receive Avastin®. It must also 
not be used for pregnant women [1].  
 
 
2 Indication 
Bevacizumab (Avastin®) is indicated for the treatment of adult patients with 
platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary 
peritoneal cancer who received no more than two prior chemotherapy regi-
mens and who have not received prior therapy with bevacizumab or other 
VEGF inhibitors or VEGF receptor–targeted agents. 
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3 Current regulatory status 
The EMA extended the licensed indication of bevacizumab on the 31st of Ju-
ly 2014 to 
b bevacizumab in combination with paclitaxel, topotecan, or pegylated 
liposomal doxorubicin for the treatment of adult patients with plati-
num-resistant recurrent epithelial ovarian, fallopian tube, or primary 
peritoneal cancer who received no more than two prior chemotherapy 
regimens and who have not received prior therapy with bevacizumab 
or other VEGF inhibitors or VEGF receptor–targeted agents. 
The EMA has also approved Avastin® for the following indications [1]: 
b Front-line treatment of adult patients with advanced (FIGO [Fédéra-
tion Internationale de Gynécologie et d'Obstétrique]) stages III B, 
IIIC, IV) epithelial ovarian, fallopian tube or primary peritoneal can-
cer (in combination with carboplatin and paclitaxel). 
b Adult patients with first recurrence of platinum-sensitive epithelial 
ovarian, fallopian tube or primary peritoneal cancer who have not re-
ceived prior therapy with bevacizumab or other VEGF inhibitors or 
VEGF receptor-targeted agents (in combination with carboplatin or 
gemcitabine). 
b First-line treatment of adult patients with metastatic breast cancer 
(combination with paclitaxel). 
b First-line treatment of adult patients with metastatic breast cancer in 
combination with capecitabine (when other chemotherapy options 
including taxanes or anthracyclines are not considered appropriate). 
b Adult patients with unresectable, advanced, metastatic or recurrent 
non-small cell lung cancer (in addition to platinum-based chemo-
therapy). 
b In combination with fluoropyrimidine-based chemotherapy it is indi-
cated for treatment of adult patients with metastatic carcinoma of the 
colon or rectum. 
b First-line treatment of adult patients with advanced and/or metastat-
ic renal cancer (in combination with interferon alfa-2a). 
 
In the U.S., the FDA has not yet approved Avastin® for the treatment of 
platinum-resistant recurrent epithelial ovarian, fallopian tube or primary 
peritoneal cancer. However, it is licensed for [3]: 
b Patients with metastatic colorectal cancer, combined with intrave-
nous 5-fluorouracil-based chemotherapy for first- or second-line 
treatment. 
b The second-line treatment in combination with fluoropyrimidine-, 
irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for 
patients with metastatic colorectal cancer who have progressed on a 
first-line Avastin®-containing regimen [3].  
b Non-squamous non-small cell lung cancer (in combination with car-
boplatin and paclitaxel, for first-line treatment of unresectable, local-
ly advanced, recurrent or metastatic disease). 
EMA approved 
bevacizumab for 
platinum-resistant 
epithelial ovarian cancer 
in July 2014 
indication not yet 
approved by the FDA 
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b Glioblastoma in adult patients with progressive disease following pri-
or therapy (used as single agent). 
b Patients with metastatic renal cell carcinoma in combination with in-
terferon alfa [3]. 
 
 
4 Burden of disease 
Epithelial ovarian cancer, fallopian tube and primary peritoneal cancer 
show similar clinical characteristics and behaviour. Therefore, they are often 
considered collectively [4].  
Ovarian cancer forms in tissues of the ovary [5]. 95% of ovarian malignan-
cies are derived from epithelial cells [6]. Epithelial ovarian cancer remains 
the fourth most frequent cause of cancer death in European women. Addi-
tionally, it is the most lethal gynaecological tumour in Western Countries [7, 
8]. 21,980 new cases are expected in the US in 2014 [9] and in Austria, 646 
women were newly diagnosed with ovarian cancer in 2011 [10]. Overall, the 
annual age-adjusted death rate per year of patients suffering from ovarian 
cancer was 7.5 per 100,000 women in the US and 5.3 per 100,000 women in 
Austria in 2011, respectively [9]. 
Therefore, ovarian cancer is the eighth most frequent cancer and it repre-
sents approximately 4% of all tumours in Austrian women. However, ac-
cording to Statistik Austria, the incidence of ovarian cancer and disease-
related death rate continuously declined over the past decades (e.g., reduc-
tion of disease-related death rate of 11% over the last ten years) [10, 11]. 
The median age at diagnosis of ovarian cancer is 63 years (out of these wom-
en 12% are < 45 years, 41.2% are between 45 and 64 years, and 44.5% are ≥ 
65 years at time of diagnosis) [12]. Since the incidence of epithelial ovarian 
cancer increases with age, the prevalence (57/100,000 women) is highest in 
the eighth decade of life [13]. 
Different systems are available to classify cancer stages. The most commonly 
used for staging ovarian cancer are the FIGO (Fédération International de 
Gynécologie et d’Obstétrique) and the TNM (tumour, node, metastasis) stag-
ing system. The five general stages of the FIGO system are: 
b Stage 0: “Pre-cancer” or carcinoma in situ. 
b Stage I: Tumour limited to ovaries. 
b Stage II: Tumour involves one or both ovaries with pelvic extension 
and/or implants 
b Stage III: Tumour involves one or both ovaries with microscopically 
confirmed peritoneal metastasis outside the pelvis. 
b Stage IV: Patient shows distant metastasis [14]. 
Signs and symptoms of ovarian cancer occur very late; therefore, over 75% of 
ovarian cancer patients suffer from advanced stage III or stage IV disease at 
the time of diagnosis [15, 16].  
After cytoreductive surgery and platinum-based adjuvant chemotherapy in 
combination with paclitaxel, several factors (disease stage, age, etc.) play an 
epithelial ovarian, 
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essential role in disease relapse. Patients with stage I/II disease show a re-
lapse rate of 10-20%, whereas patients at advanced stage III-IV ovarian can-
cer have relapses in 60-85% of cases [4].  
Age is also considered as a risk factor for relapse and survival. Whilst wom-
en under 40 years have a five-year survival rate of 65%, only 20% of ovarian 
cancer patients older than 40 years are alive five years after diagnosis [4]. 
Besides age and null parity, risk factors for developing the disease are early 
age of menarche, late age of menopause and family history of ovarian, breast 
or endometrial (uterine) cancer [17]. An identifiable genetic predisposition 
(e.g. BRCA1/BRCA2) is present in only 10% to 15% of patients [18]. 
Depending on the response to therapy, epithelial ovarian cancer can be di-
vided into:  
b platinum-refractory: patients progressing during therapy or within 
four weeks after the last dose;  
b platinum-resistant: patients progressing within six months of plati-
num-based therapy; 
b platinum-sensitive: patients progressing with an interval of more 
than 12 months 
b partially platinum-sensitive: patients progressing between six and 
12 months [19, 20]. 
Women with platinum-resistant or platinum-refractory disease usually have 
a poor prognosis (i.e., expected overall survival < 12 months) [19].  
 
 
5 Current treatment 
Since about 80% of patients with ovarian cancer will relapse after first-line 
platinum-based and taxane-based chemotherapy, the choice of second-line 
therapy does not primarily depend on risk factors such as age or stage of dis-
ease, but rather on the progression-free interval from the last chemothera-
peutic regimen [4, 15, 19, 21]. Recommended second-line treatment options 
for platinum-recurrent/resistant ovarian cancer patients are: 
b paclitaxel, 
b pegylated liposomal doxorubicin,  
b topotecan, 
b  or gemcitabine [15, 19, 22].  
Due to the poor prognosis, treatment should focus on improving the quality 
of life and on alleviating symptoms [19]. 
Although combination regimens with non-cross-resistant agents are associ-
ated with higher objective response rates and a two- to three-month im-
provement in progression-free survival (PFS), they were also more toxic in 
clinical trials. Therefore, single-agent therapy is the standard of care for 
platinum-resistant/refractory ovarian cancer patients [4]. Rarely, re-
treatment with platinum drugs may also be used as a treatment option.  
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of disease, nulliparous, 
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several active agents in 
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6 Evidence 
A systematic literature search was conducted in Embase, Ovid Medline, the 
CRD Database and the Cochrane Library on the 28th of July 2014. 660 refer-
ences were identified. Additionally, the manufacturer was contacted, and 
submitted seven [23-29] abstracts and one full-text publication [30] which 
had already been identified by our systematic search.  
Articles were excluded when results for platinum-resistant and platinum-
sensitive were not provided separately, and if patients had received more 
than a mean of two prior lines of therapy.  
Therefore, only trials with the following criteria were included: 
b Platinum-resistant epithelial ovarian, fallopian tube or primary 
peritoneal cancer. 
b No previous bevacizumab therapy.  
b Mean ≤ 2 prior treatment lines. 
Ultimately, one phase III trial [30] and five phase II trials [31-35] were in-
cluded in this report. 
 
6.1 Efficacy and safety – Phase III studies 
Table 1: Summary of efficacy 
Study title  
Bevacizumab Combined with Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The 
AURELIA Open-Label Randomized Phase III Trial [30, 36, 37] 
Study  
identifier 
AURELIA trial, NCT00976911 (ClinicalTrials.gov Identifier), MO22224 (Protocol 
number), 2009-011400-33 (EUDRACT-number) 
Design Phase III, randomised, open-label, multicentre 
Duration  Enrolment: October 2009–April 2011 
Median follow-up: 13.9 months in the control group, 13.0 months 
in the intervention group 
Cut-off date for primary analysis: November 2011  
Cut-off date for final OS analysis: January 2013 
Hypothesis Superiority 
sample size of ≥ 360 patients was calculated to provide 80% power with a one-sided 
log-rank test at 0.05, assuming a hazard ratio (HR) of 0.72, corresponding to median 
PFS of 4.0 months with chemotherapy versus 5.56 months with bevacizumab-
chemotherapy 
Funding Hoffmann-La Roche 
Treatment 
groups 
Patients allocated Overall: 361 
Intervention 
(n=179) 
Bevacizumab: 10 mg/kg IV every two weeks or 15 mg/kg IV every 
three weeks (for patient receiving topotecan)  
plus  
Paclitaxel: 80 mg/m2 IV on days 1, 8, 15 and 22 of each 4-week 
cycle 
one phase III trial and 
five phase II trials 
included 
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Topotecan: 4 mg/m2 IV on days 1, 8 and 15 of each 4-week cycle, 
or 1.25 mg/m2 on days 1-5 of each 3-week cycle 
Pegylated liposomal doxorubicin: 40 mg/m2 IV every four weeks 
Control 
(n=182) 
Single-agent chemotherapy at the investigators’ discretion: 
Paclitaxel: 80 mg/m2 IV on days 1, 8, 15 and 22 of each 4-week 
cycle 
Topotecan: 4 mg/m2 IV on days 1, 8 and 15 of each 4-week cycle, 
or 1.25 mg/m2 on days 1-5 of each 3-week cycle 
Pegylated liposomal doxorubicin: 40 mg/m2 IV every four weeks 
Endpoints 
and 
definitions 
Progression-free 
survival 
(primary outcome) 
PFS Investigator-assessed PFS by RECIST criteria, defined as 
interval between random assignment and first 
radiologically documented progression of disease or 
death, whichever occurs first 
Objective response 
rate 
ORR Objective response rate according to RECIST and/or 
GCIG CA-125 criteria 
Overall survival OS Time from date of randomisation to the date of death 
from any cause. 
Quality of life QoL Assessed by using questionnaires such as EORTC, HADS, 
FOSI, which measure quality of life at weeks 8, 16, 24 or 
8, 18 and 27 
Results and analysis 
Analysis  
description 
Intention-to-treat 
By using an unstratified, two-sided log-rank test, the PFS of the intervention and 
control group was compared. Additionally, a post-hoc analysis was performed by using 
an unstratified, two-sided log-rank test. After the death of 70% of patients, a final OS 
analysis was done.  
Analysis  
population 
Inclusion b Patients ≥ 18 years of age 
b Histologically confirmed epithelial ovarian, fallopian tube or 
primary peritoneal cancer (measurable by RECIST or GCIG CA-
125) 
b Platinum-resistant disease (progression within < 6 months of 
completing ≥ 4 cycles of platinum-based therapy) 
b ECOG performance status 0-2 
Exclusion b Previous treatment with > 2 prior anticancer regimens 
b Platinum-refractory disease 
b Non-epithelial tumours 
b Ovarian tumours with low malignant potential 
b Prior radiotherapy to the pelvis or abdomen 
b Surgery (incl. open biopsy) within four weeks before starting 
study medication 
b Anticipated need for major surgery during study treatment 
b Treatment with another investigational drug within 30 days 
prior to first study dose 
b Untreated CNS or symptomatic CNS metastasis 
b Thrombotic or haemorrhagic disorders within six months before 
first study dose 
b Uncontrolled hypertension 
b Active clinically significant cardiovascular disease 
b Non-healing wound, ulcer or bone fracture 
Characteristics Median age, years (range): C 61 (25–84), I 62 (25–80) 
Histological grade at diagnosis, number (%):  
1: C 9 (5), I 10 (6) 
2: C 48 (26), I 53 (30) 
3: C 105 (58), I 94 (53) 
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Missing: C 20 (11), I 22 (12) 
Prior anti-angiogenic therapy, number (%): C 14 (8), I 12 (7) 
Two prior CT regimens, number (%): C 78 (43), I 72 (40) 
ECOG Performance Status, number (%):  
0: C 99 (54), I 107 (60) 
1: C 69 (38), I 58 (32) 
2: C 11 (6), I 12 (7) 
Missing: C 3 (2), I 2 (1) 
Measurable disease, number (%): C 144 (79), I 143 (80) 
Ascites, number (%): C 54 (30), I 59 (33) 
Descriptive 
statistics 
and 
estimated 
variability 
Treatment group Chemotherapy only  Bevacizumab + 
chemotherapy 
Number of subjects N = 182 N = 179 
Median PFS, months  
(95% CI) 
3.4  
(2.2 to 3.7) 
6.7  
(5.7 to 7.9) 
Median OS, months  
(95% CI) 
13.3  
(11.9 to 16.4) 
16.6 
(13.7 to 19.0) 
ORR (measurable by RECIST), % 
[n = 287] 
 
11.8 
(p = .001) 
 
27.3 
(p = .001) 
 
PRO (measurable by QLQ-OV28) 
≥ 15% improvement in 
abdominal/GI symptoms n (%) at 
week 8/9 
15 (9.3) 
 
 
34 (21.9) 
 
 
Effect 
estimate per 
comparison 
Comparison groups  Bevacizumab + 
chemotherapy vs 
Chemotherapy only 
Median PFS HR 0.48 
95% CI 0.38 to 0.60 
P value  < .001 
OS HR 0.85 
95% CI 0.66 to 1.08 
P value < .174 
ORR  
(measurable by RECIST and/or 
GCIG CA-125) 
Percentage point 
difference 
18.3 
95% CI 9.6 to 27.0 
P value < .001 
≥ 15% improvement in 
abdominal/GI symptoms 
measurable by QLQ-OV28 
Percentage point 
difference 
12.7 
95% CI 4.4 to 20.9 
P value 0.002 
Abbreviations: NCT = National Clinical Trial; IV = intravenous; PFS = progression-free survival; OS = overall survival; 
ORR = objective response rate; PRO = patient-reported outcome; ST = safety and toxicity; RECIST = Response Evaluation 
Criteria in Solid Tumours; GCIG CA-125 = Gynaecological Cancer Intergroup Cancer Antigen 125; EORTC QLQ-C30 = 
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire, Cancer Module C30; EORTC 
QLQ-OV28 = European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire, Ovarian Cancer 
Module 28; FOSI = Functional Assessment of Cancer Therapy-Ovarian Cancer Symptoms Index; AEs = adverse events; 
ECOG = Eastern Cooperative Oncology Group; CNS = central nerve system; CI = confidence interval 
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Table 2: Summary of grade ≥ 3 adverse events of special interest 
Study ID: NCT00976911 
Grade (according  
to CTC version 3.0) Outcome, n (%) 
Control 
(n=181) 
Intervention 
(n=179) 
Grade ≥ 3 Hypertension 2 (1) 13 (7) 
Proteinuria 0 (0) 3 (2) 
Gastrointestinal (GI) perforation 0 (0) 3 (2) 
Fistula/abscess 0 (0) 2 (1) 
Bleeding 2 (1) 2 (1) 
Wound healing complications  0 (0) 0 (0) 
Thromboembolic event arterial 0 (0) 4 (2) 
Thromboembolic event venous 8 (4) 5 (3) 
Congestive heart failure 1 (1) 1 (1) 
Cardiac disorders 0 (0) 0 (0) 
Others Deaths, not considered due to 
primary progressive disease 
5 (2.8) 5 (2.8) 
 
In this open-label, randomised phase III trial, 361 patients were enrolled 
and randomised either to a single-agent chemotherapy or to a chemotherapy 
in combination with bevacizumab (Avastin®) [30]. The choice of chemother-
apeutic regimen (i.e., topotecan, pegylated liposomal doxorubicin or 
paclitaxel) was at the investigator’s discretion. Eligible patients had an epi-
thelial ovarian, fallopian tube or primary peritoneal cancer (measurable by 
RECIST or by Gynecologic Cancer Intergroup CA 125 Response Definition) 
that had progressed within < 6 months after completing ≥ 4 cycles of plati-
num-based therapy. Patients with platinum-refractory disease, with more 
than two prior chemotherapy regimens and those with a bowel obstruction 
related to an underlying disease were excluded [30, 36]. Only patients with 
ECOG performance status 0–2 were included. Most of the enrolled patients 
showed a histological grade 3 tumour at diagnosis; only about 7% had re-
ceived prior antiangiogenic therapy [30]. 
The AURELIA trial demonstrated a statistically significant improvement in 
investigator-assessed PFS, the primary outcome, for platinum-resistant ovar-
ian cancer patients treated with bevacizumab and a chemotherapy regimen. 
The median PFS in the group treated with single-agent chemotherapy was 
3.4 months (95% CI 2.2 to 3.7). In comparison, the median PFS was 6.7 
months (95% CI 5.7 to 7.9) for the combination group, yielding a hazard ra-
tio of 0.48. The PFS was consistent in subgroups according to age, measura-
ble disease and ascites. For patients younger than 65 years, the hazard ratio 
was 0.49 and for elderly patients (≥ 65 years) 0.47 respectively. Patients with 
ascites had a hazard ratio of 0.40, whereas patients without ascites yielded a 
hazard ratio of 0.48. In the subgroup analyses, the hazard ratio ranged from 
0.40 to 0.53 [30]. 
With a median overall survival (OS) of 13.3 months (95% CI 11.9 to 16.4) in 
the control group and 16.6 months (95% CI 13.7 to 19.0) in patients addi-
tionally treated with bevacizumab, there was no statistically significant dif-
ference between the two treatment options. However, these results may be 
influenced by the fact that upon evidence of disease progression patients 
were allowed to cross-over to the combination arm; consequently about 40% 
of patient in the chemotherapy arm crossed over to bevacizumab and chemo-
therapy [30]. 
361 patients were 
enrolled comparing 
bevacizumab + 
chemotherapy to 
chemotherapy 
 
platinum-refractory 
disease , no more than 2 
prior therapies 
significant improvement 
of PFS (3.4 vs. 6.7 
months) 
no statistically 
significant difference of 
OS 
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During the study period, five deaths (2.8% of patients) in each group which 
were not primarily caused by disease progression were reported. Infection 
with neutropenia, cardiac failure, septic shock, peritonitis and gastrointesti-
nal (GI) haemorrhage were the causes of death in the control group. Patients 
in the bevacizumab and chemotherapy group died due to infection with neu-
tropenia, GI haemorrhage, GI perforation, cardiac arrest and shock [30].  
Regarding side effects, the AURELIA trial showed similar results as previ-
ous studies with bevacizumab in ovarian cancer. Hypertension and pro-
teinuria ≥ grade 2 were more common in the treatment arm with bevaci-
zumab. 20% of patients treated with this regimen showed a hypertension 
and 2% showed a proteinuria. Grade 3 adverse events such as GI perforation, 
proteinuria, fistula/abscess and reversible posterior leukoencephalopathy 
syndrome only occurred in the treatment arm with bevacizumab. Bleeding, 
thromboembolic event, wound-healing complication and congestive heart 
failure (≥ grade 3) occurred in both groups [30]. 
43.6% of patients in the intervention group experienced grade 2–5 adverse 
events and therefore discontinued study treatment, in comparison to 8.8% in 
the single-agent chemotherapy group. The median time to withdrawal from 
study treatment in the combination therapy group was 5.2 months, com-
pared to 2.4 months in the chemotherapy only group. Regarding the sub-
group of patients older than 65 years, the rates of discontinuation due to ad-
verse events were 8.8% (chemotherapy arm) versus 50.0% (combination with 
bevacizumab) [2, 30]. 
 
For the analysis of patient-reported outcomes (PROs), the primary hypothe-
sis was that more patients treated with bevacizumab would experience ≥ 
15% improvement in abdominal/GI symptoms at week 8/9 measured by the 
European Organisation for Research and Treatment of Cancer Quality of 
Life Questionnaire (EORTC), Ovarian Cancer Module 28. From the overall 
361 patients allocated to AURELIA, 317 (88%) completed the baseline ques-
tionnaire, 206 (57%) filled in the questionnaires at week 8/9 and 129 (36%) 
at week 16/18. Fewer results are available for the chemotherapy group, 
where only 24% completed the 16-/18-week follow-up in comparison with 
48% in the bevacizumab and chemotherapy group. At week 8/9, 34 (21.9%) 
of patients allocated to bevacizumab and chemotherapy showed the above 
mentioned improvement in comparison to 15 (9.3%) patients in the single-
agent chemotherapy. The difference, therefore, was 12.7% favouring bevaci-
zumab (95% CI 4.4 to 20.9%; p = .002). Also at week 16/18, significantly 
more patients dedicated to bevacizumab showed a ≥ 15% improvement in 
abdominal/GI symptoms, i.e. 15.5% in the bevacizumab group and 5.6% in 
the chemotherapy group. This yielded a difference of 9.9% (95% CI 2.9 to 
17.0%; p = .005). A mixed-model repeated-measures analysis for the ab-
dominal/GI subscale of the EORTC was performed to summarise the effects 
of the two treatment arms. It demonstrates a 6.4-point difference (CI 95% 
1.3 to 11.6; p=.015) favouring the group treated with bevacizumab and 
chemotherapy [37]. 
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6.2 Efficacy and safety – further studies 
Bevacizumab + topotecan  
40 patients (mean age 58.6 years) were enrolled in this phase II trial [38]. In-
clusion criterion was primary or secondary platinum-resistant disease. Pa-
tients were treated, in median, with eight cycles of bevacizumab 10 mg/kg 
on days 1 and 15. In addition, they received topotecan 4 mg/m2 on days 1, 8 
and 15 of a 4-week cycle until the progression of disease or excessive toxicity 
occurred. 21 (53%) patients had one prior treatment regimen, whereas 19 
(47%) had already received two prior therapies. The median PFS (RECIST 
criteria) was 7.8 months (95% CI 3.0 to 9.4) and the OS was 16.6 months 
(95% CI 12.8 to 22.9) in all patients. Ten patients (25%) had partial re-
sponse (PR), 14 patients (35%) had stable disease (SD) and 16 patients 
(40%) had a progressive disease (PD). 55% of patients were progression-free 
for more than six months. Most of the toxicities were classified as mild or 
moderate.  
The most common adverse events ≥ grade 3 were hypertension (20%), neu-
tropenia (18%), gastrointestinal toxicity (18%), metabolic toxicity (16%) or 
pain (13%) [32].  
 
Bevacizumab + paclitaxel 
Another phase II study by Tillmanns et al. [33] investigated bevacizumab 
with albumin-bound paclitaxel in patients with recurrent, platinum-
resistant epithelial ovarian or primary peritoneal cancer. The 48 patients en-
rolled (mean age 61.0 years) received ab-paclitaxel 100 mg/m2 IV on days 1, 
8 and 15 with bevacizumab 10 mg/kg IV on days 1 and 15 every four weeks 
(28 days). The patients had received a mean of 1.8 (range 1.0–6.0) prior 
treatment lines. All patients were treated until disease progression.  
The median PFS measured by RECIST criteria was 8.08 months (95% CI 
5.78 to 10.15) and the median OS was 17.15 months (95% CI 13.57 to 23.82). 
Four patients (8.3%) showed a complete response (CR) and 20 patients 
(41.7%) had a PR, yielding an overall response rate (ORR) of 50% (95% CI 
34.8% to 65.1%). 14 patients (29.2%) had an SD, eight patients (16.7%) had 
a PD and two patients (4.2%) could not be evaluated. 
Nearly half of the patients (43.8%) had at least one grade 3 non-serious ad-
verse event and four patients (8%) experienced a grade 4 event. The most 
frequent toxicities were gastrointestinal (16.7%), vascular disorders (6.3%), 
as well as infections and infestations (6.3%) [33]. 
 
Bevacizumab + pegylated liposomal doxorubicin (PLD) 
46 patients (mean age 64 years) participated in the phase II study and they 
received a treatment regimen with bevacizumab 15 mg/kg (starting at cycle 
2) and PLD 30 mg/m2 every three weeks [34].  
The median of prior treatment lines was 2.0 (range 1.0–3.0). The median 
PFS (by GCIC criteria) was 6.6 months (95% CI 5.5 to 8.7) and 7.8 months 
(95% CI 6.4 to 9.7) by RECIST criteria. 33.2 months (95% CI 18.8 to not ap-
plicable) was the OS. The ORR measured by RECIST criteria was 30%, four 
patients (9%) had CR, nine patients (21%) had PR and 24 patients (56%) 
had SD.  
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Several adverse events occurred during this trial. Mucositis (64%), palmar-
plantar erythrodysesthesia (PPE)/ulceration (52%), asthenia (52%) and 
rash/pruritus (50%) were the most common non-haematological toxicities. 
No treatment-related deaths were observed. The most frequent grade 3 toxic-
ities were PPE/ulceration and hypertension. The most common adverse 
events related to the administration of bevacizumab were hypertension 
(46%), headaches (41%) and epistaxis (21%) [34].  
 
Bevacizumab + pemetrexed  
In the phase II study, 34 patients (mean age 61.5 years) were enrolled [31]. 
The administration of pemetrexed 500 mg/m2 IV and bevacizumab 15 mg/kg 
IV was given every three weeks. 35% of the patients were platinum-resistant 
with a median PFS of 6.7 (95% CI 4.1 to 9.9) months and an OS of 16.7 
months. 53% of all patients (platinum-resistant and platinum-sensitive) 
showed hematologic side effects (grade 3–4).  
The most frequent grade 3–4 adverse events were neutropenia (47%), leuko-
penia (27%), metabolic toxicity (24%) and pain (21%). Fatigue occurred in 
nearly all patients (94%), but was mostly (76%) of grade 1-2. The treatment 
combination of bevacizumab and pemetrexed is an active combination for 
platinum-resistant and platinum-sensitive recurrent ovarian cancer [31].  
 
Bevacizumab + docetaxel 
This phase II trial investigated the safety and efficacy of bevacizumab (15 
mg/kg) on day one of a 3-week cycle and docetaxel (40 mg/m2) on days 1 and 
8 [35]. In this trial, 41 patients (mean age 58.2 years) with a platinum-free 
interval < 12 months were enrolled. The median PFS for the 19 patients 
with a platinum-free interval < 6 months was 6.2 months (95% CI 4.1 to 
4.7). 
Regarding the response rates and the toxicities, no distinction between plat-
inum-resistant and platinum-sensitive can be made. ORR was 56.4% with 
the majority, i.e., 55.3 being PR. Six patients (15.8%) had PD and ten pa-
tients (26.3%) had SD. 65.9% of the patients experienced grade 3–4 toxicity. 
The most frequent grade 3–4 adverse events were neutropenia (14.6%), fa-
tigue (12.2%), leukopenia (12.2%) and metabolic/laboratory toxicity (12.2%) 
[35].  
 
7 Estimated costs 
The recommended dosage for Avastin® in patients with recurrent platinum-
resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer is 
10 mg/kg bodyweight every two weeks or 15 mg/kg bodyweight every three 
weeks [30].  
Avastin® is available in vials of 4 ml (25 mg/ml) and in vials of 16 ml (25 
mg/ml). The costs for Avastin® are € 414 for the 4 ml vials, and € 1,421 for 
the 16 ml vials [39]. The overall treatment costs for one cycle of Avastin® 
(assuming 10 mg/kg are administered every two weeks by using one 16 ml 
vial and two 4 ml vials) for a woman assuming a body weight of 60 kg would 
therefore be approximately € 4,500. In the AURELIA trial, the median dura-
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tion of bevacizumab was six cycles, leading to total costs of € 27,000. In addi-
tion, the costs for the previous treatment regimens, prior surgery and the 
treatment of the side effects accrue.  
 
 
8 Ongoing research 
In August 2014 no on-going phase III trials investigating bevacizumab 
(Avastin®) for patients with recurrent platinum-resistant, epithelial ovarian, 
fallopian tube or primary peritoneal cancer were found at ClinicalTrials.gov 
and clinicaltrialsregister.eu. 
Two ongoing phase II trials are registered: 
b NCT01936974: This study investigates platinum-gemcitabine-
avastin (PGA) for platinum-resistant/refractory, paclitaxel-
pretreated recurrent ovarian and peritoneal carcinoma. September 
2014 is the estimated primary completion date.  
b NCT01652079: A phase II, 2-stage trial of CRLX101 in combina-
tion with bevacizumab in recurrent platinum-resistant ovarian, tu-
bal and peritoneal cancer. The estimated primary completion date 
is April 2016.  
At the moment there are various ongoing phase III trials investigating 
bevacizumab for different types of cancer such as head and neck cancer, col-
orectal and breast cancer. In addition, several trials investigate bevacizumab 
for already approved indications like glioblastoma or advanced non-small 
cell lung cancer.  
 
9 Commentary 
Since the end of July 2014, the EMA has approved bevacizumab (Avastin®) 
in combination with paclitaxel, topotecan, or pegylated liposomal doxorubi-
cin for the treatment of adult patients with platinum-resistant recurrent epi-
thelial ovarian, fallopian tube, or primary peritoneal cancer who received no 
more than two prior chemotherapy regimens and who have not received pri-
or therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–
targeted agents [1, 2].  
This decision was based on the findings of a randomised phase III trial 
(AURELIA) that investigated the combination of bevacizumab with chemo-
therapy in comparison to chemotherapy alone for platinum-resistant recur-
rent ovarian cancer. Only patients who had received < 2 prior anticancer 
regimen and no prior VEGF therapy were eligible [30].  
This trial demonstrated a statistically significant improvement in PFS for 
platinum-resistant ovarian cancer patients treated with bevacizumab and 
chemotherapy in comparison to chemotherapy alone, a setting where only 
suboptimal treatment options are available. The administration of bevaci-
zumab in combination with paclitaxel, topotecan or pegylated liposomal 
no ongoing phase III 
trials 
 
two ongoing phase II 
trial investigating 
bevacizumab 
EMA has approved 
Avastin® for epithelial 
ovarian cancer 
impact of efficacy, 
safety and quality of life 
was investigated 
significant improvement 
of PFS in bevacizumab + 
chemotherapy 
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doxorubicin resulted in an absolute gain in median PFS of 3.3 months and 
reduced the risk of progression or death by 52%. Noteworthy is the fact that 
the PFS was assessed by investigators and not by an independent review 
committee; the results, therefore, could have been influenced [30]. However, 
an independent review of data confirmed these findings [40]. Regarding OS, 
with 13.3 months in median OS for the control group and 16.6 months for 
the patients treated additionally with bevacizumab, there was no statistically 
significant difference between the two treatment options [30]. However, 
these results are compromised due to the fact that 40% of patients crossed-
over from single-agent chemotherapy to bevacizumab in addition to a chem-
otherapy regimen [30, 41]. 
Regarding side effects, the AURELIA trial showed similar results as previ-
ous studies with bevacizumab in ovarian cancer. GI perforation, neutropenia 
and hypertension also occurred in several phase II trials investigating 
bevacizumab in combination with a chemotherapy regimen [31-35].Grade 3 
adverse events such as gastrointestinal (GI) perforation, proteinuria, fistu-
la/abscess and reversible posterior leukoencephalopathy syndrome only oc-
curred in the bevacizumab arm. Hypertension and proteinuria grade≥ 2 
were more common in the treatment arm with bevacizumab; 20% of patients 
treated with this regimen had hypertension and 2% had proteinuria [30] in 
comparison to 7% and 0% in the chemotherapy only arm.  
Bevacizumab can be associated with serious adverse events and the toxicities 
can sometimes be life-threatening. Therefore, the improvement of quality 
and life, as well as alleviation of symptoms, plays an important role in the 
decision of the treatment regimen for patients with platinum-resistant re-
current epithelial ovarian, fallopian tube or primary peritoneal cancer [41, 
42]. Some indications for a positive impact on quality of life can be derived 
from patients included in the AURELIA trial. The main hypothesis, i.e., 
that more patients in the bevacizumab arm will experience a ≥ 15% im-
provement in abdominal/GI symptoms, showed a statistically significant dif-
ference favouring bevacizumab [37]. 
However, findings related to quality of life have to put into perspective; due 
to the open-label design of this trial, results may be potentially biased in fa-
vour of the bevacizumab arm. Moreover, the permission of crossover could 
have an influence on this outcome [41, 42] and as mentioned by the authors 
themselves, a considerable number of patients overall and even more in the 
chemotherapy group did not complete the questionnaires at the follow-up 
mainly because patients with progressive disease were not assessed. Missing 
data was then rated as non-responders. How to deal with missing data in 
PRO analyses is still under discussion, but it may be the case that some pa-
tients with progressive disease did not experience aggravation of symptoms.  
The larger number of missing questionnaires in the chemotherapy only 
group, may have therefore contributed to a more favourable result for the 
bevacizumab and chemotherapy group. When missing data was excluded 
from the analysis, the result did not become statistically significant [41]. 
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Even though the AURELIA trial has found improved results in terms of 
PFS and response rate for bevacizumab in addition to chemotherapy, the 
question posed is when and in which setting bevacizumab can derive the 
greatest benefit. Bevacizumab in combination with chemotherapy is also li-
censed in the front-line setting, but only 7% of patients in the bevacizumab 
group were previously treated with VEGF therapy. Therefore, it remains 
unknown if patients previously treated with bevacizumab will have compa-
rable results to those included in the phase III study [41]. Due to the lack of 
an arm assessing bevacizumab monotherapy only, outcomes for the sequen-
tial use of bevacizumab and chemotherapy rather than administration of 
combination therapy as initial regimen for platinum-resistant ovarian can-
cer cannot be derived [41]. Since monotherapy may be less toxic than com-
binations with cytotoxic regimens, this should be considered in further trials 
[30]. 
Cost considerations are also associated with questions on the optimal se-
quencing and setting of bevacizumab therapy. Several economic analyses did 
not prove cost-effectiveness generally, but rather for patients at high-risk 
[43, 44]. Biomarkers or factors predictive of response to bevacizumab in pa-
tients with ovarian cancer have thus been suggested for patient selection. 
However, no reliable biomarker has been defined yet and, therefore, further 
studies are required to confirm the clinical usefulness of markers [43]. 
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